News

Myomo Certified as Medicare Provider

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services under the U.S. Department of Health and Human Services has authorized the Company to be a Medicare Provider. Read more >>
Read more...

Wasabi Featured in 2020 CRN Cloud Partner Program Guide

Wasabi, the hot cloud storage company, today announced that it has been featured in the CRN®, a brand of The Channel Company, 2020 Cloud Partner Program Guide. The annual list identifies industry-leading cloud technology vendors with innovative partner programs that empower and accelerate the growth of solution providers’ cloud initiatives. Read more >>
Read more...

SplitSpot Signs Agreement to Acquire Assets of PlaceMe

SplitSpot, a Boston-based co-living platform, has acquired substantial assets of PlaceMe in a deal recently finalized. With the addition, SplitSpot enhances its position as a co-living leader in Boston, with several hundred rooms on its platform. SplitSpot will immediately transition the operations of a significant amount of the units previously managed by PlaceMe. Read more >>
Read more...

We Need Entrepreneurial Leaders Now More Than Ever

Two years ago, David Zamarin wowed the judges on Shark Tank with a water and stain repellent spray, walking away with $200,000 in investments for his startup Detrapel. When the coronavirus struck, Zamarin applied that same entrepreneurial mindset to a new need, pivoting his companyin a matter of weeks to make hand sanitizer and cleaning products. Read more >>
Read more...

Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis (SSc). Read more >>
Read more...